161 related articles for article (PubMed ID: 23683475)
1. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
[TBL] [Abstract][Full Text] [Related]
2. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
[TBL] [Abstract][Full Text] [Related]
3. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Stattin P; Vickers AJ; Sjoberg DD; Johansson R; Granfors T; Johansson M; Pettersson K; Scardino PT; Hallmans G; Lilja H
Eur Urol; 2015 Aug; 68(2):207-13. PubMed ID: 25682340
[TBL] [Abstract][Full Text] [Related]
4. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume.
Vertosick EA; Zappala S; Punnen S; Hugosson J; Boorjian SA; Haese A; Carroll P; Cooperberg M; Bjartell A; Lilja H; Vickers AJ
Urology; 2021 Nov; 157():102-106. PubMed ID: 34450175
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of kallikrein forms and β-microseminoprotein in blood from patients with evidence of detectable levels of PSA after radical prostatectomy.
Pellegrino F; Sjoberg DD; Tin AL; Benfante NE; Briganti A; Montorsi F; Scardino PT; Eastham JA; Vickers AJ; Lilja H; Laudone VP
World J Urol; 2023 Jun; 41(6):1489-1495. PubMed ID: 37209144
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.
Buzzoni C; Auvinen A; Roobol MJ; Carlsson S; Moss SM; Puliti D; de Koning HJ; Bangma CH; Denis LJ; Kwiatkowski M; Lujan M; Nelen V; Paez A; Randazzo M; Rebillard X; Tammela TL; Villers A; Hugosson J; Schröder FH; Zappa M
Eur Urol; 2015 Nov; 68(5):885-90. PubMed ID: 25791513
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS;
JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254
[TBL] [Abstract][Full Text] [Related]
8. The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.
Braun AE; Chan JM; Neuhaus J; Cowan JE; Kenfield SA; Van Blarigan EL; Tenggara I; Broering JM; Simko JP; Carroll PR; Cooperberg MR
Cancer; 2024 May; 130(10):1766-1772. PubMed ID: 38280206
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Relapse of Prostate Cancerafter Radical Prostatectomy in Chinese Population.
You P; Xu L; Tang L; Wang C
Urol J; 2024 May; 21(3):155-161. PubMed ID: 38088088
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
Remmers S; Bangma CH; Godtman RA; Carlsson SV; Auvinen A; Tammela TLJ; Denis LJ; Nelen V; Villers A; Rebillard X; Kwiatkowski M; Recker F; Wyler S; Zappa M; Puliti D; Gorini G; Paez A; Lujan M; Nieboer D; Schröder FH; Roobol MJ
Eur Urol; 2023 Nov; 84(5):503-509. PubMed ID: 37088597
[TBL] [Abstract][Full Text] [Related]
11. Predicting Prostate Cancer Recurrence After Radical Prostatectomy.
Jeffers A; Sochat V; Kattan MW; Yu C; Melcon E; Yamoah K; Rebbeck TR; Whittemore AS
Prostate; 2017 Feb; 77(3):291-298. PubMed ID: 27775165
[TBL] [Abstract][Full Text] [Related]
12. Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years.
Vertosick EA; Häggström C; Sjoberg DD; Hallmans G; Johansson R; Vickers AJ; Stattin P; Lilja H
J Urol; 2020 Aug; 204(2):281-288. PubMed ID: 32125228
[TBL] [Abstract][Full Text] [Related]
13. [Difference between prostate cancer patients' Gleason scores from preoperative biopsy and those from postoperative pathology].
Zhao XD; Liu YH; Hu J; Wang ZH; Jin XX; Ma MF; Zhou YL; Chen YH; Cao J; Dong J; Xu S
Zhonghua Nan Ke Xue; 2023 May; 29(5):393-401. PubMed ID: 38602754
[TBL] [Abstract][Full Text] [Related]
14. Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.
Li QK; Chen L; Ao MH; Chiu JH; Zhang Z; Zhang H; Chan DW
Theranostics; 2015; 5(3):267-76. PubMed ID: 25553114
[TBL] [Abstract][Full Text] [Related]
15. Dr. Answer AI for Prostate Cancer: Predicting Biochemical Recurrence Following Radical Prostatectomy.
Park J; Rho MJ; Moon HW; Kim J; Lee C; Kim D; Kim CS; Jeon SS; Kang M; Lee JY
Technol Cancer Res Treat; 2021; 20():15330338211024660. PubMed ID: 34180308
[TBL] [Abstract][Full Text] [Related]
16. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Klein RJ; Halldén C; Cronin AM; Ploner A; Wiklund F; Bjartell AS; Stattin P; Xu J; Scardino PT; Offit K; Vickers AJ; Grönberg H; Lilja H
Cancer Prev Res (Phila); 2010 May; 3(5):611-9. PubMed ID: 20424135
[TBL] [Abstract][Full Text] [Related]
17. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy.
Lokeshwar SD; Ali A; Weiss TR; Reynolds J; Shuch BM; Ferencz T; Kyriakides TC; Mehal WZ; Brito J; Renzulli J; Leapman MS
BMC Urol; 2024 May; 24(1):102. PubMed ID: 38702664
[TBL] [Abstract][Full Text] [Related]
18. Genetically adjusted PSA levels for prostate cancer screening.
Kachuri L; Hoffmann TJ; Jiang Y; Berndt SI; Shelley JP; Schaffer KR; Machiela MJ; Freedman ND; Huang WY; Li SA; Easterlin R; Goodman PJ; Till C; Thompson I; Lilja H; Van Den Eeden SK; Chanock SJ; Haiman CA; Conti DV; Klein RJ; Mosley JD; Graff RE; Witte JS
Nat Med; 2023 Jun; 29(6):1412-1423. PubMed ID: 37264206
[TBL] [Abstract][Full Text] [Related]
19. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy.
Hoey C; Ahmed M; Fotouhi Ghiam A; Vesprini D; Huang X; Commisso K; Commisso A; Ray J; Fokas E; Loblaw DA; He HH; Liu SK
J Transl Med; 2019 May; 17(1):173. PubMed ID: 31122242
[TBL] [Abstract][Full Text] [Related]
20. Predicting contralateral extraprostatic extension in unilateral high-risk prostate cancer: a multicentric external validation study.
Diamand R; Roche JB; Lacetera V; Simone G; Windisch O; Benamran D; Fourcade A; Fournier G; Fiard G; Ploussard G; Roumeguère T; Peltier A; Albisinni S
World J Urol; 2024 Apr; 42(1):247. PubMed ID: 38647728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
